Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010

SEOUL - South Korea's biosimilar front-runner Celltrion reported an all-time record high performance for sales and net profit in 2010, mainly from sales of its biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab) to countries in South America, the Middle East and Asia